APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD)

Département de Psychologie, Faculté des Sciences, Université de Rouen, 76821 Mont-Saint-Aignan Cedex, France.
Neuroscience & Biobehavioral Reviews (Impact Factor: 10.28). 02/2012; 36(5):1357-75. DOI: 10.1016/j.neubiorev.2012.02.011
Source: PubMed

ABSTRACT The discovery of gene mutations responsible for autosomal dominant Alzheimer's disease has enabled researchers to reproduce in transgenic mice several hallmarks of this disorder, notably Aβ accumulation, though in most cases without neurofibrillary tangles. Mice expressing mutated and wild-type APP as well as C-terminal fragments of APP exhibit variations in exploratory activity reminiscent of behavioural and psychological symptoms of Alzheimer dementia (BPSD). In particular, open-field, spontaneous alternation, and elevated plus-maze tasks as well as aggression are modified in several APP transgenic mice relative to non-transgenic controls. However, depending on the precise murine models, changes in open-field and elevated plus-maze exploration occur in either direction, either increased or decreased relative to controls. It remains to be determined which neurotransmitter changes are responsible for this variability, in particular with respect to GABA, 5HT, and dopamine.

Download full-text


Available from: Robert Lalonde, Aug 07, 2015
  • Source
    • "The increased activity found in the present study could be related to a worsening of the neurodegenerative disorder . In this respect, Lalonde et al. (2012) found an age-dependent hyperactivity in Tg2576 mice. CPF exposure was associated with changes in anxiety-related behavior. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chlorpyrifos (CPF) is an organophosphate pesticide. This pesticide induces cognitive impairments, oxidative stress and neuronal damage, which suggests a possible relationship between CPF exposure and Alzheimer's disease. In this study we examined long-term changes in behavior and brain levels of the amyloid beta (Aβ) protein after repeated CPF exposure in a mouse model of Alzheimer's disease. Tg2576 male mice between four and six months of age carrying the human Swedish mutation for Alzheimer's disease were exposed to eight doses of 25 mg/kg of CPF distributed over four weeks. Five months after exposure, general activity was measured in an open-field, while learning and memory were assessed in a Morris water maze task six months after treatment with CPF. Levels of the Aβ fragments (1-40 and 1-42) were also measured in the frontal cortex and hippocampal brain regions. Motor activity was increased in CPF-exposed mice. Although acquisition learning in a water maze task was not affected, retention was worsened in CPF-exposed mice. There were no significant increases of Aβ levels in the brains of CPF-treated mice six months after exposure. These findings raise concerns about the risk of developing neurodegenerative diseases in vulnerable subjects following repeated exposure to CPF.
    Food and Chemical Toxicology 08/2014; 72. DOI:10.1016/j.fct.2014.07.036 · 2.90 Impact Factor
  • Source
    • "Although several reviews of murine Alzheimer models have appeared (Van Leuven, 2000; Ashe, 2001; Morgan, 2003; Sant' Angelo et al., 2003; German and Eisch, 2004; Mineur et al., 2005; Spires and Hyman, 2005; McGowan et al., 2006; Gimenez-Llort et al., 2007; Duyckaerts et al., 2008; Howlett and Richardson, 2009; Kokjohn et al., 2009; Ashe and Zahs, 2010; Wirths and Bayer, 2010; Scearce-Levie, 2011; Lalonde et al., 2012), the authors mostly describe the effects of accumulating Aβ concentrations on synaptic activity or learning abilities in various spatial and non-spatial tasks. We present in-depth task-by-task effects of APP transgenesis on survival and basic neurologic functions regarding pathological reflexes, myoclonus, and epilepsy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The discovery of gene mutations underlying autosomal dominant Alzheimer's disease has enabled researchers to reproduce several hallmarks of this disorder in transgenic mice, notably the formation of Aβ plaques in brain and cognitive deficits. APP transgenic mutants have also been investigated with respect to survival rates, neurologic functions, and motor coordination, which are all susceptible to alteration in Alzheimer dementia. Several transgenic lines expressing human mutated or wild-type APP had higher mortality rates than non-transgenic controls with or without the presence of Aβ plaques. Mortality rates were also elevated in APP transgenic mice with vascular amyloid accumulation, thereby implicating cerebrovascular factors in the precocious death observed in all APP transgenic models. In addition, myoclonic jumping has been described in APP mutants, together with seizure activity, abnormal limb-flexion and paw-clasping reflexes, and motor coordination deficits. The neurologic signs resemble the myoclonic movements, epileptic seizures, pathological reflexes, and gait problems observed in late-stage Alzheimer's disease.
    Reviews in the neurosciences 08/2012; 23(4):363-79. DOI:10.1515/revneuro-2012-0041 · 3.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aberrant activation of signaling pathways plays a pivotal role in central nervous system disorders, such as Alzheimer's disease (AD). Using a combination of virtual screening and experimental testing, novel small molecule inhibitors of tPA-mediated extracellular signal-regulated kinase (Erk)1/2 activation were identified that provide higher levels of neuroprotection from Aβ-induced apoptosis than Memantine, the most recently FDA approved drug for AD treatment. Subsequent target deconvolution efforts revealed that they all share low micromolar affinity for the imidazoline I2 receptor, while being devoid of any significant affinity to a list of AD-relevant targets, including the N-methyl-D-aspartate receptor (NMDAR), acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B). Targeting the imidazoline I2 receptor emerges as a new mechanism of action to inhibit tPA-induced signaling in neurons for the treatment of AD and other neurodegenerative diseases.
    Journal of Medicinal Chemistry 10/2012; 55(22). DOI:10.1021/jm301055g · 5.48 Impact Factor
Show more